|1.||Pepine, Carl J: 32 articles (11/2015 - 12/2003)|
|2.||Gong, Yan: 15 articles (11/2015 - 06/2007)|
|3.||Cooper-DeHoff, Rhonda M: 14 articles (11/2015 - 12/2003)|
|4.||Messerli, Franz H: 13 articles (01/2015 - 12/2003)|
|5.||Cooper-Dehoff, Rhonda M: 13 articles (03/2014 - 07/2005)|
|6.||Champion, Annette: 12 articles (08/2010 - 01/2007)|
|7.||Handberg, Eileen M: 10 articles (01/2015 - 12/2003)|
|8.||Zhou, Qian: 10 articles (11/2009 - 01/2007)|
|9.||Johnson, Julie A: 9 articles (11/2015 - 06/2007)|
|10.||INVEST Investigators: 8 articles (08/2013 - 12/2003)|
|1.||Hypertension (High Blood Pressure)
09/01/1993 - "A double-blind, crossover study was carried out to compare the antihypertensive efficacy of the long-acting ACE inhibitor trandolapril 1 mg administered once daily and 0.5 mg twice daily in 31 patients with mild to moderate essential hypertension. "
02/01/2007 - "This study evaluated the effectiveness of an escalating-dose regimen of trandolapril in subjects with stage 1 or stage 2 hypertension. "
08/01/2006 - "The aim of this study was to assess the influence of trandolapril on blood pressure and ET-1 plasma activity in young patients with essential mild-to-moderate hypertension. "
02/01/1996 - "Since some once-daily agents are more effective than others in maintaining antihypertensive effects toward the end of the 24-h dosing interval this study was designed to evaluate the duration of antihypertensive action of trandolapril using 48 h ambulatory blood pressure monitoring (ABPM) in 41 patients with mild-to-moderate essential hypertension. "
01/01/1994 - "Long-term therapy with trandolapril, a new nonsulfhydryl ACE inhibitor, in hypertension: a multicenter international trial. "
07/01/1999 - "In the diabetic group, trandolapril reduced the risk of progression to severe heart failure markedly (RR, 0.38 [0.21 to 0.67]), and no significant reduction of this end point was found in the nondiabetic group. "
09/01/1998 - "Thus, whereas the initial systemic vasodilating and inotropic effects did not persist, long-term trandolapril results in sustained neurohormonal modulation, reduced preload, and improved organ perfusion, indicated by a persistent increase in renal blood flow and preservation of renal function in severe heart failure."
06/10/2014 - "Furthermore, among patients in the top quartile of FGF-23 levels, trandolapril significantly reduced cardiovascular death or incident heart failure (hazard ratio: 0.45; 95% confidence interval: 0.28 to 0.72), whereas there was no clinical benefit in the remaining patients (hazard ratio: 1.07; 95% confidence interval: 0.75 to 1.52; p interaction = 0.0039). "
01/01/2005 - "Compared with the placebo group, the trandolapril group had a significantly reduced risk of all-cause mortality (relative risk 0.89, 95% CI 0.80-0.99, P=0.03), all-cause hospitalizations (rate ratio 0.92, 95% CI 0.88-0.96, P<0.001), and cardiovascular hospitalizations (rate ratio 0.95, 95% CI 0.91-1.00, P=0.047), including congestive heart failure hospitalizations (rate ratio 0.85, 95% CI 0.77-0.93, P<0.001). "
12/03/2003 - "Trandolapril was also recommended for patients with heart failure, diabetes, or renal impairment. "
04/01/2006 - "In the TRACE trial, in patients with reduced left ventricular function after myocardial infarction, trandolapril reduced the frequency of AF. "
01/01/2007 - "Long-term treatment of the CAL rats with trandolapril improved the hemodynamic parameters, attenuated the CAL-induced increase in Hsp60 content, the decrease in mitochondrial OCR, and the increase in the mitochondrial TRS content of the viable LV at the 8th week after myocardial infarction. "
03/01/2005 - "In this study, the addition of trandolapril did not confer any additional benefit in terms of reducing the incidence of cardiovascular death, myocardial infarction, or coronary revascularization. "
01/01/2005 - "This study comprises 6676 consecutive patients with acute myocardial infarction screened for entry into the Danish Trandolapril Cardiac Evaluation (TRACE) study. "
10/01/2003 - "Recent randomized trials with trandolapril after myocardial infarction and physiologic pacing have given some insight into how this might be accomplished."
01/01/1994 - "In the mesenteric artery, trandolapril treatment induced a complete regression of the media hypertrophy and a marked decrease in extracellular matrix surface. "
01/01/1994 - "Similarly, trandolapril produced a marked decrease in vascular wall hypertrophy in both the mesenteric artery and the aorta. "
01/01/1999 - "These results show that together with hypertrophy, the abnormal mechanical properties observed in the coronary arterial wall of SHR were improved by a low dose of trandolapril treatment. "
01/01/1994 - "The effects of trandolapril on blood pressure and on cardiac and vascular hypertrophy were analyzed in comparison with the control group. "
07/01/1992 - "Trandolapril significantly limited the development of myocardial hypertrophy, decreasing the heart weight and left ventricular hypertrophic area and increasing the left ventricular myocyte nuclear density, but these effects, starting after 3-6 months, were delayed compared to the hemodynamic ones. "
|5.||Left Ventricular Dysfunction
08/01/2010 - "The study population comprised 6676 MI patients screened for entry into the TRACE study, a double-blind, randomized, parallel group, placebo-controlled study of trandolapril vs. placebo in patients with left ventricular dysfunction after MI. "
01/01/1998 - "Data from the Trandolapril Cardiac Event study, in which 1749 patients with an enzyme verified AMI and echocardiographic evidence of left ventricular dysfunction were randomized in a double-blind manner to treatment with trandolapril or placebo, were retrospectively analysed. "
01/01/2003 - "In patients with left ventricular dysfunction after myocardial infarction, the large TRACE trial showed that mortality was reduced and life expectancy increased with trandolapril treatment."
01/01/2003 - "Trandolapril in left ventricular dysfunction after myocardial infarction: focus on the TRACE study."
01/01/2001 - "Early neurohormonal effects of trandolapril in patients with left ventricular dysfunction and a recent acute myocardial infarction: a double-blind, randomized, placebo-controlled multicentre study."
|2.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|8.||Calcium Channels (Calcium Channel)
|2.||Surgical Instruments (Clip)